Legend Biotech (NASDAQ:LEGN) and Johnson & Johnson’s (NYSE:JNJ) Janssen Pharmaceuticals division have signed a component and product supply agreement for Carvykti (ciltacabtagene autoleucel) under which the former will manufacture for the latter the CAR-T treatment for clinical and commercial use globally except for greater China.
The arrangement replaces a temporary agreement signed by the two companies on Feb. 28, 2022.
Terms call for Janssen to pay Legend a transfer price for Carvykti that reflects the therapy’s production cost, plus a markup. However, the total costs necessary for production will be shared equally.
Janssen will also supply Legend Biotech with lentivirus, unprocessed cells, and certain other raw materials at a price equivalent to Janssen’s total costs to do so, plus a markup.
